Molecular genetic aberrations in the pathogenesis of multiple myeloma

[1] Bird SA, Boyd K. Multiple myeloma: an overview of management. Palliat Care Soc Pract. 2019; 13. doi: 10.1177/117822421986823 BirdSA BoydK Multiple myeloma: an overview of management Palliat Care Soc Pract. 2019 13 10.1177/117822421986823 Open DOISearch in Google Scholar

[2] Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H, et al. Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J. 2015; 5:e349. doi: 10.1038/bcj.2015.79 OzakiS HandaH SaitohT MurakamiH ItagakiM AsaokuH Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma Blood Cancer J. 2015 5 e349 10.1038/bcj.2015.79 Open DOISearch in Google Scholar

[3] Lee SJ, Tien HF, Park HJ, Kim JA, Lee DS. Gradual increase of chronic lymphocytic leukemia incidence in Korea, 1999–2010: comparison to plasma cell myeloma. Leuk Lymphoma. 2016; 57:585–9. LeeSJ TienHF ParkHJ KimJA LeeDS Gradual increase of chronic lymphocytic leukemia incidence in Korea, 1999–2010: comparison to plasma cell myeloma Leuk Lymphoma. 2016 57 585 9 Search in Google Scholar

[4] Tang CH, Liu HY, Hou HA, Qiu H, Huang KC, Siggins S, et al. Epidemiology of multiple myeloma in Taiwan, a population based study. Cancer Epidemiol. 2018; 55:136–41. TangCH LiuHY HouHA QiuH HuangKC SigginsS Epidemiology of multiple myeloma in Taiwan, a population based study Cancer Epidemiol. 2018 55 136 41 Search in Google Scholar

[5] Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975; 36:842–54. DurieBG SalmonSE A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival Cancer. 1975 36 842 54 Search in Google Scholar

[6] Mogollón P, Díaz-Tejedor A, Algarín EM, Paíno T, Garayoa M, Ocio EM. Biological background of resistance to current standards of care in multiple myeloma. Cells. 2019; 8:1432. doi: 10.3390/cells8111432 MogollónP Díaz-TejedorA AlgarínEM PaínoT GarayoaM OcioEM Biological background of resistance to current standards of care in multiple myeloma Cells. 2019 8 1432 10.3390/cells8111432 Open DOISearch in Google Scholar

[7] Pan D, Richter J. Where we stand with precision therapeutics in myeloma: prosperity, promises, and pipedreams. Front Oncol. 2022; 11:819127. doi: 10.3389/fonc.2021.819127 PanD RichterJ Where we stand with precision therapeutics in myeloma: prosperity, promises, and pipedreams Front Oncol. 2022 11 819127 10.3389/fonc.2021.819127 Open DOISearch in Google Scholar

[8] Saxe D, Seo EJ, Bergeron MB, Han JY. Recent advances in cytogenetic characterization of multiple myeloma. Int J Lab Hematol. 2019; 41:5–14. SaxeD SeoEJ BergeronMB HanJY Recent advances in cytogenetic characterization of multiple myeloma Int J Lab Hematol. 2019 41 5 14 Search in Google Scholar

[9] Hu L, Ru K, Zhang L, Huang Y, Zhu X, Liu H, et al. Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine. Biomark Res. 2014; 2:3. doi: 10.1186/2050-7771-2-3 HuL RuK ZhangL HuangY ZhuX LiuH Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine Biomark Res. 2014 2 3 10.1186/2050-7771-2-3 Open DOISearch in Google Scholar

[10] Corre J, Munshi N, Avet-Loiseau H. Genetics of multiple myeloma: another heterogeneity level? Blood. 2015; 125:1870–6. CorreJ MunshiN Avet-LoiseauH Genetics of multiple myeloma: another heterogeneity level? Blood. 2015 125 1870 6 Search in Google Scholar

[11] Barwick BG, Gupta VA, Vertino PM, Boise LH. Cell of origin and genetic alterations in the pathogenesis of multiple myeloma. Front Immunol. 2019; 10:1121. doi: 10.3389/fimmu.2019.01121 BarwickBG GuptaVA VertinoPM BoiseLH Cell of origin and genetic alterations in the pathogenesis of multiple myeloma Front Immunol. 2019 10 1121 10.3389/fimmu.2019.01121 Open DOISearch in Google Scholar

[12] Prideaux SM, Conway O’Brien E, Chevassut TJ. The genetic architecture of multiple myeloma. Adv Hematol. 2014; 2014:864058. doi: 10.1155/2014/864058 PrideauxSM Conway O’BrienE ChevassutTJ The genetic architecture of multiple myeloma Adv Hematol. 2014 2014 864058 10.1155/2014/864058 Open DOISearch in Google Scholar

[13] Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C; Groupe Français de Cytogénétique Hématologique. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001; 98:2229–38. SmadjaNV BastardC BrigaudeauC LerouxD FruchartC Groupe Français de Cytogénétique Hématologique Hypodiploidy is a major prognostic factor in multiple myeloma Blood. 2001 98 2229 38 Search in Google Scholar

[14] Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM, et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003; 102:2562–7. FonsecaR Debes-MarunCS PickenEB DewaldGW BryantSC WinklerJM The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma Blood. 2003 102 2562 7 Search in Google Scholar

[15] Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, et al. High-resolution genomic profiles define distinct clinicopathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006; 9:313–25. CarrascoDR TononG HuangY ZhangY SinhaR FengB High-resolution genomic profiles define distinct clinicopathogenetic subgroups of multiple myeloma patients Cancer Cell. 2006 9 313 25 Search in Google Scholar

[16] Chng WJ, Santana-Dávila R, Van Wier SA, Ahmann GJ, Jalal SM, Bergsagel PL, et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia. 2006; 20:807–13. ChngWJ Santana-DávilaR Van WierSA AhmannGJ JalalSM BergsagelPL Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations Leukemia. 2006 20 807 13 Search in Google Scholar

[17] Chretien ML, Corre J, Lauwers-Cances V, Magrangeas F, Cleynen A, Yon E, et al. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? Blood. 2015; 126:2713–9. ChretienML CorreJ Lauwers-CancesV MagrangeasF CleynenA YonE Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? Blood. 2015 126 2713 9 Search in Google Scholar

[18] Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004; 64:1546–58. FonsecaR BarlogieB BatailleR BastardC BergsagelPL ChesiM Genetics and cytogenetics of multiple myeloma: a workshop report Cancer Res. 2004 64 1546 58 Search in Google Scholar

[19] Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol. 2007; 20:571–96. ChngWJ GlebovO BergsagelPL KuehlWM Genetic events in the pathogenesis of multiple myeloma Best Pract Res Clin Haematol. 2007 20 571 96 Search in Google Scholar

[20] Tian E, Sawyer JR, Heuck CJ, Zhang Q, van Rhee F, Barlogie B, Epstein J. In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes. Genes Chromosomes Cancer. 2014; 53:549–57. TianE SawyerJR HeuckCJ ZhangQ van RheeF BarlogieB EpsteinJ In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes Genes Chromosomes Cancer. 2014 53 549 57 Search in Google Scholar

[21] Mirabella F, Wu P, Wardell CP, Kaiser MF, Walker BA, Johnson DC, Morgan GJ. MMSET is the key molecular target in t(4;14) myeloma. Blood Cancer J. 2013; 3:e114. doi: 10.1038/bcj.2013.9 MirabellaF WuP WardellCP KaiserMF WalkerBA JohnsonDC MorganGJ MMSET is the key molecular target in t(4;14) myeloma Blood Cancer J. 2013 3 e114 10.1038/bcj.2013.9 Open DOISearch in Google Scholar

[22] Kalff A, Spencer A. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood Cancer J. 2012; 2:e89. doi: 10.1038/bcj.2012.37 KalffA SpencerA The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies Blood Cancer J. 2012 2 e89 10.1038/bcj.2012.37 Open DOISearch in Google Scholar

[23] Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 2002; 100:1579–83. MoreauP FaconT LeleuX MorineauN HuygheP HarousseauJL Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy Blood. 2002 100 1579 83 Search in Google Scholar

[24] Sibley K, Fenton JA, Dring AM, Ashcroft AJ, Rawstron AC, Morgan GJ. A molecular study of the t(4;14) in multiple myeloma. Br J Haematol. 2002; 118:514–20. SibleyK FentonJA DringAM AshcroftAJ RawstronAC MorganGJ A molecular study of the t(4;14) in multiple myeloma Br J Haematol. 2002 118 514 20 Search in Google Scholar

[25] Chan H, Phillips M, Maganti M, Farooki S, Piza Rodriguez G, Masih-Khan E, et al. Single-center experience in treating patients with t(4;14) multiple myeloma with and without planned frontline autologous stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2018; 18:225–34. ChanH PhillipsM MagantiM FarookiS Piza RodriguezG Masih-KhanE Single-center experience in treating patients with t(4;14) multiple myeloma with and without planned frontline autologous stem cell transplantation Clin Lymphoma Myeloma Leuk. 2018 18 225 34 Search in Google Scholar

[26] Avet-Loiseau H, Malard F, Campion L, Magrangeas F, Sebban C, Lioure B, et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood. 2011; 117:2009–11. Avet-LoiseauH MalardF CampionL MagrangeasF SebbanC LioureB Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood. 2011 117 2009 11 Search in Google Scholar

[27] Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006; 108:3289–94. AttalM HarousseauJL LeyvrazS DoyenC HulinC BenboubkerL Maintenance therapy with thalidomide improves survival in patients with multiple myeloma Blood. 2006 108 3289 94 Search in Google Scholar

[28] Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002; 100:1417–24. FonsecaR BaileyRJ AhmannGJ RajkumarSV HoyerJD LustJA Genomic abnormalities in monoclonal gammopathy of undetermined significance Blood. 2002 100 1417 24 Search in Google Scholar

[29] Chang H, Qi XY, Stewart AK. t(11;14) does not predict long-term survival in myeloma. Leukemia. 2005; 19:1078–9. ChangH QiXY StewartAK t(11;14) does not predict long-term survival in myeloma Leukemia. 2005 19 1078 9 Search in Google Scholar

[30] Matulis SM, Gupta VA, Neri P, Bahlis NJ, Maciag P, Leverson JD, et al. Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. Leukemia. 2019; 33:1291–6. MatulisSM GuptaVA NeriP BahlisNJ MaciagP LeversonJD Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma Leukemia. 2019 33 1291 6 Search in Google Scholar

[31] Cardona-Benavides IJ, de Ramón C, Gutiérrez NC. Genetic abnormalities in multiple myeloma: prognostic and therapeutic implications. Cells. 2021; 10:336. doi: 10.3390/cells10020336 Cardona-BenavidesIJ de RamónC GutiérrezNC Genetic abnormalities in multiple myeloma: prognostic and therapeutic implications Cells. 2021 10 336 10.3390/cells10020336 Open DOISearch in Google Scholar

[32] Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010; 116:e56–65. WalkerBA LeonePE ChiecchioL DickensNJ JennerMW BoydKD A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value Blood. 2010 116 e56 65 Search in Google Scholar

[33] Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, et al. Outcome of multiple myeloma with chromosome 1q gain and 1p deletion after autologous hematopoietic stem cell transplantation: propensity score matched analysis. Biol Blood Marrow Transplant. 2020; 26:665–71. VarmaA SuiD MiltonDR TangG SainiN HasanO Outcome of multiple myeloma with chromosome 1q gain and 1p deletion after autologous hematopoietic stem cell transplantation: propensity score matched analysis Biol Blood Marrow Transplant. 2020 26 665 71 Search in Google Scholar

[34] Sonneveld P. Gain of 1q21 in multiple myeloma: from bad to worse? Blood. 2006; 108:1426–7. SonneveldP Gain of 1q21 in multiple myeloma: from bad to worse? Blood. 2006 108 1426 7 Search in Google Scholar

[35] Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J. 2015; 5:e365. doi: 10.1038/bcj.2015.92 RajanAM RajkumarSV Interpretation of cytogenetic results in multiple myeloma for clinical practice Blood Cancer J. 2015 5 e365 10.1038/bcj.2015.92 Open DOISearch in Google Scholar

[36] An G, Xu Y, Shi L, Shizhen Z, Deng S, Xie Z, et al. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica. 2014; 99:353–9. AnG XuY ShiL ShizhenZ DengS XieZ Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value Haematologica. 2014 99 353 9 Search in Google Scholar

[37] Grzasko N, Hajek R, Hus M, Chocholska S, Morawska M, Giannopoulos K, et al. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group. Leuk Lymphoma. 2017; 58:1–15. GrzaskoN HajekR HusM ChocholskaS MorawskaM GiannopoulosK Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group Leuk Lymphoma. 2017 58 1 15 Search in Google Scholar

[38] Maura F, Bolli N, Angelopoulos N, Dawson KJ, Leongamornlert D, Martincorena I, et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun. 2019; 10:3835. doi: 10.1038/s41467-019-11680-1 MauraF BolliN AngelopoulosN DawsonKJ LeongamornlertD MartincorenaI Genomic landscape and chronological reconstruction of driver events in multiple myeloma Nat Commun. 2019 10 3835 10.1038/s41467-019-11680-1 Open DOISearch in Google Scholar

[39] Walker BA. The chromosome 13 conundrum in multiple myeloma. Blood Cancer Discov. 2020; 1:16–7. WalkerBA The chromosome 13 conundrum in multiple myeloma Blood Cancer Discov. 2020 1 16 7 Search in Google Scholar

[40] Binder M, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, Lacy MQ, et al. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood Cancer J. 2017; 7:e600. doi: 10.1038/bcj.2017.83 BinderM RajkumarSV KetterlingRP GreippPT DispenzieriA LacyMQ Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma Blood Cancer J. 2017 7 e600 10.1038/bcj.2017.83 Open DOISearch in Google Scholar

[41] Gozzetti A, Frasconi A, Crupi R. Molecular cytogenetics of multiple myeloma. Austin J Cancer Clin Res. 2014; 1:1020. GozzettiA FrasconiA CrupiR Molecular cytogenetics of multiple myeloma Austin J Cancer Clin Res. 2014 1 1020 Search in Google Scholar

[42] Bustoros M, Sklavenitis-Pistofidis R, Park J, Redd R, Zhitomirsky B, Dunford AJ, et al. Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression. J Clin Oncol. 2020; 38:2380–9. BustorosM Sklavenitis-PistofidisR ParkJ ReddR ZhitomirskyB DunfordAJ Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression J Clin Oncol. 2020 38 2380 9 Search in Google Scholar

[43] Jenner MW, Leone PE, Walker BA, Ross FM, Johnson DC, Gonzalez D, et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood. 2007; 110:3291–300. JennerMW LeonePE WalkerBA RossFM JohnsonDC GonzalezD Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma Blood. 2007 110 3291 300 Search in Google Scholar

[44] Kim GY, Gabrea A, Demchenko YN, Bergsagel L, Roschke AV, Kuehl WM. Complex IGH rearrangements in multiple myeloma: frequent detection discrepancies among three different probe sets. Genes Chromosomes Cancer. 2014; 53:467–74. KimGY GabreaA DemchenkoYN BergsagelL RoschkeAV KuehlWM Complex IGH rearrangements in multiple myeloma: frequent detection discrepancies among three different probe sets Genes Chromosomes Cancer. 2014 53 467 74 Search in Google Scholar

[45] Mikulasova A, Ashby C, Tytarenko RG, Qu P, Rosenthal A, Dent JA, et al. Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma. Haematologica. 2020; 105:1055–66. MikulasovaA AshbyC TytarenkoRG QuP RosenthalA DentJA Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma Haematologica. 2020 105 1055 66 Search in Google Scholar

[46] Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. 2017; 130:2392–400. MoreauP Chanan-KhanA RobertsAW AgarwalAB FaconT KumarS Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM Blood. 2017 130 2392 400 Search in Google Scholar

[47] Tomas P, Miroslava V, Jiri M, Jana B, Jaroslav B, Marie J, Vlastimil S. Translocation t(8;14) in multiple myeloma defines patients with very poor prognosis – Single centre experience. Clin Lymphoma Myeloma Leuk. 2015; 15(Suppl 3):e122. doi: 10.1016/j.clml.2015.07.311 TomasP MiroslavaV JiriM JanaB JaroslavB MarieJ VlastimilS Translocation t(8;14) in multiple myeloma defines patients with very poor prognosis – Single centre experience Clin Lymphoma Myeloma Leuk. 2015 15 Suppl 3 e122 10.1016/j.clml.2015.07.311 Open DOISearch in Google Scholar

[48] Barwick BG, Neri P, Bahlis NJ, Nooka AK, Dhodapkar MV, Jaye DL, et al. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nat Commun. 2019; 10:1911. doi: 10.1038/s41467-019-09555-6 BarwickBG NeriP BahlisNJ NookaAK DhodapkarMV JayeDL Multiple myeloma immunoglobulin lambda translocations portend poor prognosis Nat Commun. 2019 10 1911 10.1038/s41467-019-09555-6 Open DOISearch in Google Scholar

[49] Misund K, Keane N, Stein CK, Asmann YW, Day G, Welsh S, et al. MYC dysregulation in the progression of multiple myeloma. Leukemia. 2020; 34:322–6. MisundK KeaneN SteinCK AsmannYW DayG WelshS MYC dysregulation in the progression of multiple myeloma Leukemia. 2020 34 322 6 Search in Google Scholar

[50] Gmidène A, Saad A, Avet-Loiseau H. 8p21.3 deletion suggesting a probable role of TRAIL-R1 and TRAIL-R2 as candidate tumor suppressor genes in the pathogenesis of multiple myeloma. Med Oncol. 2013; 30:489. doi: 10.1007/s12032-013-0489-8 GmidèneA SaadA Avet-LoiseauH 8p21.3 deletion suggesting a probable role of TRAIL-R1 and TRAIL-R2 as candidate tumor suppressor genes in the pathogenesis of multiple myeloma Med Oncol. 2013 30 489 10.1007/s12032-013-0489-8 Open DOISearch in Google Scholar

[51] Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia. 1999; 13:1817–24. GazittY TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells Leukemia. 1999 13 1817 24 Search in Google Scholar

[52] Baysal M, Demirci U, Umit E, Kirkizlar HO, Atli EI, Gurkan H, et al. Concepts of double hit and triple hit disease in multiple myeloma, entity and prognostic significance. Sci Rep. 2020; 10:5991. doi: 10.1038/s41598-020-62885-0 BaysalM DemirciU UmitE KirkizlarHO AtliEI GurkanH Concepts of double hit and triple hit disease in multiple myeloma, entity and prognostic significance Sci Rep. 2020 10 5991 10.1038/s41598-020-62885-0 Open DOISearch in Google Scholar

[53] Bolli N, Biancon G, Moarii M, Gimondi S, Li Y, de Philippis C, et al. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018; 32:2604–16. BolliN BianconG MoariiM GimondiS LiY de PhilippisC Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups Leukemia. 2018 32 2604 16 Search in Google Scholar

[54] Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, et al. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019; 33:159–70. WalkerBA MavrommatisK WardellCP AshbyTC BauerM DaviesF A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis Leukemia. 2019 33 159 70 Search in Google Scholar

[55] Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002; 99:1745–57. ZhanF HardinJ KordsmeierB BummK ZhengM TianE Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells Blood. 2002 99 1745 57 Search in Google Scholar

[56] Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007; 109:2276–84. ShaughnessyJDJr ZhanF BuringtonBE HuangY CollaS HanamuraI A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1 Blood. 2007 109 2276 84 Search in Google Scholar

[57] Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010; 116:2543–53. BroylA HoseD LokhorstH de KnegtY PeetersJ JauchA Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients Blood. 2010 116 2543 53 Search in Google Scholar

[58] Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006; 108:2020–8. ZhanF HuangY CollaS StewartJP HanamuraI GuptaS The molecular classification of multiple myeloma Blood. 2006 108 2020 8 Search in Google Scholar

[59] Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, et al. A gene expression signature for high-risk multiple myeloma. Leukemia. 2012; 26:2406–13. KuiperR BroylA de KnegtY van VlietMH van BeersEH van der HoltB A gene expression signature for high-risk multiple myeloma Leukemia. 2012 26 2406 13 Search in Google Scholar

[60] Kuiper R, van Duin M, van Vliet MH, Broijl A, van der Holt B, El Jarari L, et al. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood. 2015; 126:1996–2004. KuiperR van DuinM van VlietMH BroijlA van der HoltB El JarariL Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System Blood. 2015 126 1996 2004 Search in Google Scholar

[61] Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011; 471:467–72. ChapmanMA LawrenceMS KeatsJJ CibulskisK SougnezC SchinzelAC Initial genome sequencing and analysis of multiple myeloma Nature. 2011 471 467 72 Search in Google Scholar

[62] Corre J, Cleynen A, Robiou du Pont S, Buisson L, Bolli N, Attal M, et al. Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia. 2018; 32:2636–47. CorreJ CleynenA Robiou du PontS BuissonL BolliN AttalM Multiple myeloma clonal evolution in homogeneously treated patients Leukemia. 2018 32 2636 47 Search in Google Scholar

[63] Perrot A, Corre J, Avet-Loiseau H. Risk stratification and targets in multiple myeloma: from genomics to the bedside. Am Soc Clin Oncol Educ Book. 2018; 38:675–80. PerrotA CorreJ Avet-LoiseauH Risk stratification and targets in multiple myeloma: from genomics to the bedside Am Soc Clin Oncol Educ Book. 2018 38 675 80 Search in Google Scholar

[64] Hu Y, Chen W, Wang J. Progress in the identification of gene mutations involved in multiple myeloma. Onco Targets Ther. 2019; 12:4075–80. HuY ChenW WangJ Progress in the identification of gene mutations involved in multiple myeloma Onco Targets Ther. 2019 12 4075 80 Search in Google Scholar

[65] Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015; 33:3911–20. WalkerBA BoyleEM WardellCP MurisonA BegumDB DahirNM Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma J Clin Oncol. 2015 33 3911 20 Search in Google Scholar

[66] Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, et al. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood. 2014; 123:632–9. MulliganG LichterDI Di BaccoA BlakemoreSJ BergerA KoenigE Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy Blood. 2014 123 632 9 Search in Google Scholar

[67] Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018; 132:587–97. WalkerBA MavrommatisK WardellCP AshbyTC BauerM DaviesFE Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma Blood. 2018 132 587 97 Search in Google Scholar

[68] Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014; 5:2997. doi: 10.1038/ncomms3997 BolliN Avet-LoiseauH WedgeDC Van LooP AlexandrovLB MartincorenaI Heterogeneity of genomic evolution and mutational profiles in multiple myeloma Nat Commun. 2014 5 2997 10.1038/ncomms3997 Open DOISearch in Google Scholar

[69] Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014; 25:91–101. LohrJG StojanovP CarterSL Cruz-GordilloP LawrenceMS AuclairD Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy Cancer Cell. 2014 25 91 101 Search in Google Scholar

[70] Lionetti M, Barbieri M, Todoerti K, Agnelli L, Marzorati S, Fabris S, et al. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. Oncotarget. 2015; 6:24205–17. LionettiM BarbieriM TodoertiK AgnelliL MarzoratiS FabrisS Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation Oncotarget. 2015 6 24205 17 Search in Google Scholar

[71] Davis A, Gao R, Navin N. Tumor evolution: linear, branching, neutral or punctuated? Biochim Biophys Acta Rev Cancer. 2017; 1867:151–61. DavisA GaoR NavinN Tumor evolution: linear, branching, neutral or punctuated? Biochim Biophys Acta Rev Cancer. 2017 1867 151 61 Search in Google Scholar

[72] Rasche L, Schinke C, Maura F, Bauer MA, Ashby C, Deshpande S, et al. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nat Commun. 2022; 13:4517. doi: 10.1038/s41467-022-32145-y RascheL SchinkeC MauraF BauerMA AshbyC DeshpandeS The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states Nat Commun. 2022 13 4517 10.1038/s41467-022-32145-y Open DOISearch in Google Scholar

[73] Bergsagel PL, Kuehl WM. Promiscuous structural variants drive myeloma initiation and progression. Blood Cancer Discov. 2020; 1:221–3. BergsagelPL KuehlWM Promiscuous structural variants drive myeloma initiation and progression Blood Cancer Discov. 2020 1 221 3 Search in Google Scholar

[74] Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011; 144:27–40. StephensPJ GreenmanCD FuB YangF BignellGR MudieLJ Massive genomic rearrangement acquired in a single catastrophic event during cancer development Cell. 2011 144 27 40 Search in Google Scholar

[75] Shen MM. Chromoplexy: a new category of complex rearrangements in the cancer genome. Cancer Cell. 2013; 23:567–9. ShenMM Chromoplexy: a new category of complex rearrangements in the cancer genome Cancer Cell. 2013 23 567 9 Search in Google Scholar

[76] Ashby C, Boyle EM, Bauer MA, Mikulasova A, Wardell CP, Williams L, et al. Structural variants shape the genomic landscape and clinical outcome of multiple myeloma. Blood Cancer J. 2022; 12:85. doi: 10.1038/s41408-022-00673-x AshbyC BoyleEM BauerMA MikulasovaA WardellCP WilliamsL Structural variants shape the genomic landscape and clinical outcome of multiple myeloma Blood Cancer J. 2022 12 85 10.1038/s41408-022-00673-x Open DOISearch in Google Scholar

[77] Wiedmeier-Nutor JE, Bergsagel PL. Review of multiple myeloma genetics including effects on prognosis, response to treatment, and diagnostic workup. Life (Basel). 2022; 12:812. doi: 10.3390/life12060812 Wiedmeier-NutorJE BergsagelPL Review of multiple myeloma genetics including effects on prognosis, response to treatment, and diagnostic workup Life (Basel). 2022 12 812 10.3390/life12060812 Open DOISearch in Google Scholar

[78] Rustad EH, Yellapantula VD, Glodzik D, Maclachlan KH, Diamond B, Boyle EM, et al. Revealing the impact of structural variants in multiple myeloma. Blood Cancer Discov. 2020; 1:258–73. RustadEH YellapantulaVD GlodzikD MaclachlanKH DiamondB BoyleEM Revealing the impact of structural variants in multiple myeloma Blood Cancer Discov. 2020 1 258 73 Search in Google Scholar

[79] Tang C, Bagnara D, Chiorazzi N, Scharff MD, MacCarthy T. AID overlapping and polη hotspots are key features of evolutionary variation within the human antibody heavy chain (IGHV) genes. Front Immunol. 2020; 11:788. doi: 10.3389/fimmu.2020.00788 TangC BagnaraD ChiorazziN ScharffMD MacCarthyT AID overlapping and polη hotspots are key features of evolutionary variation within the human antibody heavy chain (IGHV) genes Front Immunol. 2020 11 788 10.3389/fimmu.2020.00788 Open DOISearch in Google Scholar

[80] Kotani A, Kakazu N, Tsuruyama T, Okazaki IM, Muramatsu M, Kinoshita K, et al. Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice. Proc Natl Acad Sci U S A. 2007; 104:1616–20. KotaniA KakazuN TsuruyamaT OkazakiIM MuramatsuM KinoshitaK Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice Proc Natl Acad Sci U S A. 2007 104 1616 20 Search in Google Scholar

[81] Maura F, Rustad EH, Yellapantula V, Łuksza M, Hoyos D, Maclachlan KH, et al. Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma. Leukemia. 2020; 34:1476–80. MauraF RustadEH YellapantulaV ŁukszaM HoyosD MaclachlanKH Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma Leukemia. 2020 34 1476 80 Search in Google Scholar

[82] Talluri S, Samur MK, Buon L, Kumar S, Potluri LB, Shi J, et al. Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma. Blood Cancer J. 2021; 11:166. doi: 10.1038/s41408-021-00554-9 TalluriS SamurMK BuonL KumarS PotluriLB ShiJ Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma Blood Cancer J. 2021 11 166 10.1038/s41408-021-00554-9 Open DOISearch in Google Scholar

[83] Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015; 6:6997. doi: 10.1038/ncomms7997 WalkerBA WardellCP MurisonA BoyleEM BegumDB DahirNM APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma Nat Commun. 2015 6 6997 10.1038/ncomms7997 Open DOISearch in Google Scholar

[84] Maura F, Petljak M, Lionetti M, Cifola I, Liang W, Pinatel E, et al. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia. 2018; 32:1044–8. MauraF PetljakM LionettiM CifolaI LiangW PinatelE Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines Leukemia. 2018 32 1044 8 Search in Google Scholar

[85] Yamazaki H, Shirakawa K, Matsumoto T, Hirabayashi S, Murakawa Y, Kobayashi M, et al. Endogenous APOBEC3B overexpression constitutively generates DNA substitutions and deletions in myeloma cells. Sci Rep. 2019; 9:7122. doi: 10.1038/s41598-019-43575-y YamazakiH ShirakawaK MatsumotoT HirabayashiS MurakawaY KobayashiM Endogenous APOBEC3B overexpression constitutively generates DNA substitutions and deletions in myeloma cells Sci Rep. 2019 9 7122 10.1038/s41598-019-43575-y Open DOISearch in Google Scholar

[86] Mateos MV, Kumar S, Dimopoulos MA, González-Calle V, Kastritis E, Hajek R, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020; 10:102. doi: 10.1038/s41408-020-00366-3 MateosMV KumarS DimopoulosMA González-CalleV KastritisE HajekR International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) Blood Cancer J. 2020 10 102 10.1038/s41408-020-00366-3 Open DOISearch in Google Scholar

[87] Oben B, Froyen G, Maclachlan KH, Leongamornlert D, Abascal F, Zheng-Lin B, et al. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nat Commun. 2021; 12:1861. doi: 10.1038/s41467-021-22140-0 ObenB FroyenG MaclachlanKH LeongamornlertD AbascalF Zheng-LinB Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities Nat Commun. 2021 12 1861 10.1038/s41467-021-22140-0 Open DOISearch in Google Scholar